Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Falkensee – page 142

1 865 clinical trials in Falkensee, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Falkensee at a glance
1 865
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 865 trials in Falkensee

Open in trial search

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Moderate to Severe Ulcerative Colitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Janssen Cilag International

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Treating Plaque Psoriasis in Special Areas for Patients with Moderate to Severe Symptoms

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Icotrokinra
  • Sponsor:Janssen Cilag International

Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:ETOP IBCSG Partners Foundation

Study on [68Ga]Ga-PentixaFor and [18F]FDG PET/CT Imaging for Staging Marginal Zone Lymphoma in Patients with Confirmed Diagnosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Gallium (68GA)
  • Sponsor:Pentixapharm AG

Primary amyloidosis

Not recruiting

Study of Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone for Patients with Newly Diagnosed AL Amyloidosis with Heart Involvement

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study on the Long-term Safety and Effects of AL002 and Florquinitau F18 in Patients with Alzheimer's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florquinitau (18F)
  • Sponsor:Alector LLC

Neoplasm malignant+2

Not recruiting

Study on Larotrectinib for Treating Children with Advanced Solid Tumors with NTRK Fusion

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Larotrectinib Sulfate
  • Sponsor:Bayer AG

Glioblastoma

Not recruiting

Study on Perampanel Treatment Before Surgery for Patients with Progressive Glioblastoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Perampanel
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Study Comparing Obinutuzumab and Venetoclax with Obinutuzumab and Chlorambucil for Untreated Chronic Lymphocytic Leukemia Patients with Other Health Conditions

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Chlorambucil
  • Sponsor:F. Hoffmann-La Roche AG

Study on Lutetium (177Lu) Vipivotide Tetraxetan and Androgen Receptor Inhibitors for Patients with Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Novartis Pharma AG

Pyoderma gangrenosum

Not recruiting

Study on Vilobelimab and Drug Combination for Treating Ulcerative Pyoderma Gangrenosum in Adults

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Betamethasone
  • Sponsor:InflaRx GmbH

Breast cancer+3

Not recruiting

Study on Abemaciclib with Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer at Intermediate to High Risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Falkensee

What the registry says about research in the country

01 Metabolic Disorders

Innovative research focusing on Type 2 Diabetes Mellitus management and glycemic control, evaluating new therapeutic approaches including novel compounds and established treatments.

  • Glycemic Control Studies
  • Cardiovascular Outcomes
  • Diabetes Management

Multiple trials are investigating both single and combination therapies for improving patient outcomes.

02 Cardiovascular Health

Comprehensive studies addressing atherosclerotic cardiovascular disease and cholesterol management, examining innovative treatments for reducing major adverse cardiovascular events.

  • Lipid Management
  • Cardiovascular Risk Reduction
  • Arterial Health

Research focuses on comparing effectiveness of different therapeutic approaches for cholesterol control.

03 Metabolic and Renal Health

Groundbreaking research combining treatments for chronic kidney disease and metabolic conditions, including studies on weight management and obesity-related complications.

  • Weight Management
  • Kidney Disease Progression
  • Blood Pressure Control

Trials evaluate combination therapies targeting multiple health conditions simultaneously.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.